Every material Form 8-K Pulmatrix, Inc. has filed with the SEC since April 21, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Pulmatrix reported a second quarter 2026 net loss of $1.0 million, or $0.29 per share, down from $1.5 million, or $0.42 per share, a year earlier, as general and administrative expenses fell. Cash and cash equivalents were $2.2 million at June 30, 2026, down from $4.1 million at December 31, 2025, and the company said clinical development is on hold while it works to license or monetize its clinical assets. The proposed merger with Eos SENOLYTIX is still expected to close in the third quarter of 2026, subject to customary closing conditions.
Net loss for the three months ended June 30, 2026 was $1.0 million ($1,036 thousand), compared with $1.5 million in the same period of 2025
General and administrative expenses were $1.0 million, down about $0.5 million from $1.5 million a year earlier
Cash and cash equivalents were $2.2 million at June 30, 2026, versus $4.1 million at December 31, 2025, and the company said this is sufficient to fund operations at least through the anticipated merger closing
Merger with Eos SENOLYTIX, announced March 26, 2026, is anticipated to close in the third quarter of 2026; Form S-4 was initially filed July 9, 2026 and amended August 3, 2026
Pulmatrix reported a first quarter 2026 net loss of $1.2 million, or $0.32 per share, down from $1.8 million, or $0.50 per share, a year earlier. Cash and cash equivalents fell to $3.3 million, and the unaudited financials include going-concern language; the company says its cash is sufficient to fund operations at least through the anticipated closing of its proposed merger with Eos SENOLYTIX, expected in the third quarter of 2026.
Net loss of $1.2 million ($0.32 per share) for the three months ended March 31, 2026, versus $1.8 million ($0.50 per share) a year earlier
General and administrative expenses fell to $1.3 million from $1.8 million, mainly due to Form S-4 costs incurred in the prior-year quarter
Cash and cash equivalents were $3.3 million at March 31, 2026, down from $4.1 million at December 31, 2025
Merger agreement with Eos SENOLYTIX signed March 26, 2026; closing anticipated in the third quarter of 2026
Pulmatrix, Inc. closed a private placement of Series B Convertible Preferred Stock on April 16, 2026, with an affiliate of Eos SENOLYTIX, Inc. The company said the investment is part of its planned merger with Eos and was made as part of the signing of the definitive merger agreement. The gross proceeds of approximately $1 million are intended for working capital and general corporate purposes.
Closed on April 16, 2026; aggregate gross proceeds of approximately $1 million before offering expenses
Preferred stock convertible into common stock at $2.20 per share, exercisable from 90 days after issuance
Investment made with an affiliate of Eos SENOLYTIX, Inc. as part of the planned merger
Securities were issued under Section 4(a)(2) and Regulation D and are not registered
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Pulmatrix, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →